studi
use
human
plasma
healthi
individu
zymosanactiv
normal
human
plasma
approv
ethic
committe
beij
institut
microbiolog
epidemiolog
procedur
compli
declar
helsinki
written
consent
obtain
plasma
donor
ethic
committe
approv
consent
procedur
procedur
involv
anim
approv
institut
anim
care
use
committe
iacuc
beij
institut
microbiolog
epidemiolog
iacuc
permit
studi
anim
carri
strict
accord
recommend
guid
care
use
laboratori
anim
highli
potent
neutral
mab
specif
human
develop
inflarx
gmbh
germani
treatment
inflammatori
diseas
wwwinflarxcom
clinic
phase
trial
demonstr
safe
well
toler
display
desir
pharmacokinet
pharmacodynam
paramet
phase
clinic
trial
regist
europ
http
materi
kindli
provid
inflarx
free
aliquot
stock
influenza
viru
strain
grown
embryon
egg
experi
involv
viru
perform
approv
biosafeti
level
facil
twelv
african
green
monkey
use
studi
ten
monkey
inocul
intratrach
tissu
cultur
infect
dose
viru
remain
monkey
mockinfect
four
virusinfect
monkey
treat
intraven
mgkg
remain
monkey
receiv
sham
intraven
treatment
detail
inform
see
supplementari
data
express
granulocyt
analyz
flow
cytomet
total
hemolyt
complement
activ
assay
standard
method
rel
express
mannosebind
serin
proteas
masp
detect
analyz
use
method
lung
viral
titer
determin
describ
previous
inflammatori
cytokin
level
monkey
plasma
sampl
measur
enzymelink
immunosorb
assay
elisa
infiltr
macrophag
neutrophil
perform
assess
immunohistochem
stain
method
previous
describ
detail
assay
use
studi
see
supplementari
data
statist
analys
perform
use
graphpad
prism
version
see
supplementari
data
abil
block
activ
human
test
use
assay
decreas
express
human
granulocyt
antibodi
antigen
ie
endogen
molar
ratio
use
figur
nm
block
zymosanactiv
plasma
zap
driven
upregul
monkey
granulocyt
figur
abil
block
mac
format
human
monkey
sera
test
use
assay
measur
abil
plasma
lyse
antibodyprim
sheep
erythrocyt
eight
human
plasma
sampl
test
without
figur
heatinactiv
plasma
neg
control
induc
lysi
dilut
wherea
untreat
plasma
potent
lyse
erythrocyt
howev
dose
rang
influenc
mac
format
similar
data
obtain
monkey
plasma
figur
thu
potent
inhibit
inflammatori
respons
human
monkey
without
impair
format
mac
unlik
mockinfect
monkey
monkey
treat
exhibit
extens
damag
lung
day
viral
infect
name
multifoc
tracheal
bronchaden
figur
bronchu
alveoli
reveal
acut
exud
diffus
pulmonari
damag
denatur
collaps
epitheli
tissu
figur
diffus
thicken
alveolar
septa
figur
moreov
endotheli
tissu
lung
denatur
exhibit
larg
number
adher
inflammatori
cell
damag
basement
membran
figur
ultrastructur
analysi
alveoli
reveal
degener
pulmonari
epitheli
cell
damag
barrier
figur
lung
tissu
mockinfect
monkey
kill
day
subject
realtim
revers
transcript
polymeras
chain
reaction
analysi
express
inde
gene
significantli
upregul
infect
monkey
figur
plasma
level
major
complement
activ
product
rose
sharpli
infect
notabl
although
level
remain
high
time
point
day
level
drop
peak
day
return
baselin
day
figur
immunohistochemistri
lung
day
also
reveal
elev
protein
express
lung
especi
bronchiol
epithelium
sever
inflam
lung
tissu
figur
lung
also
exhibit
increas
level
anoth
indic
complement
activ
figur
thu
complement
system
extens
activ
circul
lung
infect
investig
role
complement
activ
pathogenesi
lung
injuri
shamtreat
monkey
sacrif
day
viru
inocul
gross
patholog
reveal
lung
shamtreat
monkey
exhibit
multifoc
consolid
dark
red
discolor
particularli
preval
dorsal
surfac
lung
figur
contrast
lung
monkey
look
almost
normal
littl
dark
red
discolor
figur
similarli
histopatholog
analysi
show
day
infect
shamtreat
monkey
develop
pulmonari
damag
mild
multifoc
bronchointerstiti
pneumonia
wherea
monkey
exhibit
much
less
lung
patholog
specif
shamtreat
monkey
exhibit
larg
multifoc
lung
lesion
desquam
bronchiolar
epitheli
cell
degener
necrosi
alveolar
epithelium
interstiti
edema
multifoc
hemorrhag
strong
inflammatori
infiltr
wherea
monkey
exhibit
mild
moder
expans
parenchym
wall
less
interstiti
edema
significantli
less
inflammatori
cell
infiltr
figur
remain
shamtreat
monkey
sacrif
day
shamtreat
monkey
exhibit
sever
degener
bronchiolar
epitheli
cell
pneumocyt
interstiti
edema
especi
around
blood
vessel
day
wherea
monkey
show
mild
expans
parenchym
wall
less
inflammatori
cell
infiltr
less
pneumocyt
degener
interstiti
edema
observ
figur
previous
describ
semiquantit
histolog
analysi
lung
shamtreat
monkey
day
confirm
treatment
greatli
attenu
lung
histopatholog
figur
clinic
observ
infect
monkey
reveal
shamtreat
monkey
mean
bodi
temperatur
chang
day
respect
figur
exceed
p
monkey
surprisingli
day
mean
viral
titer
homogen
lung
tissu
monkey
approxim
log
lower
titer
shamtreat
monkey
p
figur
indic
lung
viral
replic
reduc
monkey
determin
pharmacokinet
monkey
model
viru
infect
plasma
level
measur
elisa
one
day
treatment
infect
treat
monkey
approxim
figur
drop
approxim
day
point
monkey
kill
day
level
remain
monkey
drop
approxim
thu
treatment
dose
decay
rel
slowli
could
potenti
influenc
bioactiv
monkey
model
infect
elucid
role
complement
activ
play
inflammatori
respons
initi
viru
infect
monkey
level
inflammatori
cytokin
chemokin
plasma
shamtreat
monkey
time
measur
elisa
figur
level
studi
inflammatori
mediat
significantli
elev
infect
shamtreat
monkey
interleukin
beta
interferon
induc
protein
monocyt
chemotact
protein
express
peak
earli
day
infect
wherea
interleukin
tumor
necrosi
factor
alpha
interferon
gamma
express
peak
day
declin
day
contrast
monkey
significantli
lower
express
level
inflammatori
mediat
overal
effect
complement
activ
cell
specif
lunginfiltr
macrophag
neutrophil
also
assess
immunohistochem
stain
lung
tissu
section
shamtreat
infect
monkey
day
show
markedli
elev
myeloperoxidas
express
figur
howev
monkey
significantli
fewer
inflammatori
infiltr
cell
lung
especi
neutrophil
figur
data
togeth
show
treatment
markedli
reduc
ali
system
inflamm
induc
viral
infect
infect
influenza
virus
highli
pathogen
avian
influenza
virus
sar
coronaviru
character
dysregul
host
immun
respons
indic
high
level
pro
antiinflammatori
cytokin
although
complement
play
import
role
host
defens
homeostasi
excess
dysregul
activ
pathogen
present
studi
establish
monkey
model
virusinduc
ali
greatli
resembl
clinic
featur
viral
pneumonia
human
lung
blood
infect
monkey
exhibit
extens
complement
activ
accompani
sever
parenchym
lesion
thu
excess
complement
activ
may
contribut
lung
damag
observ
infect
monkey
support
treatment
preclin
monkey
model
substanti
attenu
ali
induc
viru
observ
also
indic
antibodi
treatment
could
effect
intervent
viral
pneumonia
regul
complement
activ
increasingli
recogn
promis
strategi
tackl
inflammatoryrel
diseas
recombin
inhibitor
effect
substitut
therapeut
effect
sever
diseas
includ
hereditari
angioedema
myocardi
infarct
transplant
eculizumab
complementspecif
mab
approv
paroxysm
nocturn
hemoglobinuria
atyp
hemolyt
urem
syndrom
sever
promis
candid
complement
modul
also
test
variou
diseas
model
one
main
anaphylatoxin
produc
multipl
complement
activ
activ
mast
cell
basophil
caus
degranul
turn
lead
vasodil
extravas
fluid
also
particip
endotheli
activ
influenc
express
adhes
molecul
leukocyt
addit
increas
gene
express
protein
synthesi
macrophag
influenc
local
peripher
homeostasi
furthermor
function
import
chemotact
factor
affect
leukocyt
migrat
induc
synthesi
chemotact
factor
sever
line
evid
indic
modul
complement
activ
regul
could
promis
target
treatment
inflammatori
disord
note
evalu
abil
block
activ
assay
perform
zap
sourc
howev
zap
contain
high
concentr
mani
complement
activ
product
includ
fact
complet
block
zapinduc
express
granulocyt
indic
key
driver
granulocyt
activ
inflammatori
set
also
show
could
strongli
inhibit
human
monkey
clinic
sever
case
viru
infect
pneumonia
progress
rapidli
lead
ali
ard
situat
character
dysregul
inflammatori
respons
higher
viru
replic
similarli
monkey
present
studi
present
acut
pneumonia
day
infect
along
signific
system
complement
activ
high
system
level
proinflammatori
cytokin
chemokin
given
import
role
complement
defens
pathogen
upstream
posit
inflammatori
homeostasi
observ
suggest
dysregul
complement
activ
contribut
unbalanc
homeostasi
therebi
induc
proinflammatori
respons
tissu
injuri
studi
also
show
treatment
markedli
decreas
inflammatori
respons
initi
infect
attenu
virusinduc
pneumonia
date
promis
treatment
sever
viral
pneumonia
caus
sar
virus
lack
infecti
system
inflammatori
respons
syndrom
hallmark
diseas
therefor
steroid
wide
use
curb
inflamm
howev
followup
studi
shown
high
dose
steroid
use
treat
sar
caus
osteonecrosi
thu
effect
therapeut
strategi
combat
inflammatori
respons
without
induc
signific
side
effect
need
test
monkey
toxicolog
studi
human
phase
trial
demonstr
good
safeti
profil
permit
use
clinic
trial
clinic
case
sever
influenza
pneumonia
treat
oseltamivir
therefor
worthwhil
determin
potenti
synergist
antivir
effect
oseltamivir
possibl
interact
drug
futur
clinic
studi
conclus
studi
show
regul
complement
activ
may
adjunct
therapeut
option
treatment
sever
pneumonia
induc
infect
approach
may
significantli
improv
outcom
infect
human
especi
combin
antivir
treatment
strategi
